Charles Berkman

Ligand UK Ltd. is a commercial stage pharmaceutical company. Its products include Tuzistra XR, targeting the U.S. prescription cough-cold market, Moxatag, a once-a-day formulation of the antibiotic and amoxicillin, and frovatriptan, used for the acute treatment of migraine. It also develops and commercializes multiple novel products focused on the U.S. prescription cough-cold market. The company was founded by Keith G. McCullagh and Andre L. Lamotte in 1986 and is headquartered in Winnersh, the United Kingdom.

Metabasis Therapeutics, Inc. engages in discovery, development and commercialization of novel drugs for metabolic diseases using the proprietary technology and the knowledge of processes and pathways within the liver that are useful for liver-selective drug targeting and treatment of metabolic diseases. Metabasis was incorporated in April 1997 and is headquartered in La Jolla, CA.

Baker & McKenzie LLP provides legal services. The company was founded in 1949 and is headquartered in Chicago, IL.

Part of Ligand Pharmaceuticals, Inc., Ligand UK Research Ltd. develops pharmaceutical products. The private company is based in London, UK. Founded in 1995.

Lyon & Lyon, Inc. engages in the provision of legal services. The company was founded on September 4, 1979 and is headquartered in San Diego, CA.

Pfenex, Inc. is a development and licensing Biotechnology Company, which focuses on leveraging its Pfenex Expression Technology platform for developing and improving protein therapies. Its products include PF708, PF743, PF745, CRM197, PF810, PF753 and PFXX. The company was founded on November 19, 2009 and is headquartered in San Diego, CA.

Founded in 1995, Ligand UK Group Ltd. is a subsidiary of Ligand Pharmaceuticals, Inc. and functions as an investment holding private company. The company is based in Cambridge, UK.